Collegium Pharmaceutical, Inc. (COLL) - What Are Researchers Saying About This Stock?

Key Points

• Collegium beat Q3 estimates, reporting adjusted EPS of $1.96 versus $1.86 expected and revenue of $216.3 million, up 67.4% year over year. EPS nevertheless declined from $2.25 a year earlier.
• The company reaffirmed 2026 revenue guidance of $825 million–$855 million, with the midpoint above consensus, and announced a $50 million accelerated share repurchase.
• Analyst views remain broadly positive, with a “Moderate Buy” consensus, but some firms cut price targets; Piper Sandler lowered its target to $28 and gave the stock a Neutral rating. Shares fell 3.8% to $24.21 on Friday.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) has received an average rating of "Moderate Buy" from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $44.88.

Several brokerages have recently weighed in on COLL. Barclays decreased their target price on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an "overweight" rating for the company in a research note on Wednesday, August 19th. Truist Financial began coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 9th. They set a "buy" rating and a $49.00 price target on the stock. Wall Street Zen raised shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating in a research note on Saturday. Oppenheimer assumed coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 23rd. They issued an "outperform" rating and a $50.00 price objective on the stock. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $35.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday.

Collegium Pharmaceutical News Roundup

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Q3 adjusted earnings of $1.96 per share topped consensus estimates, and revenue of $216.3 million narrowly beat expectations. The company reported record quarterly revenue, including JORNAY PM revenue up 24% year over year. Collegium Q3 2026 results
• Positive Sentiment: FY 2026 revenue guidance is $825 million–$855 million, a range whose midpoint is above the $832.9 million consensus estimate. Collegium also announced a $50 million accelerated share repurchase. Collegium Q3 2026 results
• Neutral Sentiment: Needham lowered its price target from $46 to $44 but maintained a Buy rating, indicating continued optimism alongside a more cautious valuation. Needham lowers Collegium price target
• Negative Sentiment: Piper Sandler cut its target sharply, from $43 to $28, and assigned a Neutral rating. The lower valuation outlook could weigh on sentiment despite the target remaining above the referenced share price. Piper Sandler rating
• Negative Sentiment: EPS declined from $2.25 in the year-ago quarter to $1.96, tempering the earnings beat. Collegium Q3 earnings

Collegium Pharmaceutical Stock Down 3.8%

Shares of COLL stock traded down $0.95 during trading hours on Friday, reaching $24.21. The company had a trading volume of 775,375 shares, compared to its average volume of 622,329. The company has a market capitalization of $788.28 million, a P/E ratio of 24.21, a price-to-earnings-growth ratio of 0.74 and a beta of 0.75. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03. Collegium Pharmaceutical has a twelve month low of $21.43 and a twelve month high of $50.79. The stock's fifty day simple moving average is $22.99 and its 200 day simple moving average is $32.79.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 EPS for the quarter, topping the consensus estimate of $1.86 by $0.10. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The firm had revenue of $216.34 million for the quarter, compared to analyst estimates of $216.03 million. During the same period in the previous year, the company posted $2.25 EPS. Collegium Pharmaceutical's revenue for the quarter was up 67.4% on a year-over-year basis. As a group, sell-side analysts expect that Collegium Pharmaceutical will post 6.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Freestone Grove Partners LP purchased a new stake in Collegium Pharmaceutical during the 2nd quarter worth approximately $1,611,000. Globeflex Capital L P purchased a new position in shares of Collegium Pharmaceutical during the 2nd quarter valued at approximately $1,915,000. Bank of America Corp DE purchased a new position in shares of Collegium Pharmaceutical during the 2nd quarter valued at approximately $9,882,000. Empowered Funds LLC purchased a new position in shares of Collegium Pharmaceutical during the 2nd quarter valued at approximately $2,045,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Collegium Pharmaceutical during the 2nd quarter valued at approximately $8,506,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.